>Mercado de imagens de ensaios clínicos da Ásia-Pacífico, por produto e serviços (serviços e software), modalidade ( tomografia computadorizada , ressonância magnética, ecocardiografia, medicina nuclear, tomografia por emissão de positrões , raio X, ultrassom, tomografia de coerência óptica e outros), aplicação (Oncologia, Neurologia, Endocrinologia, Cardiologia, Dermatologia, Hematologia e outros), Utilizador final (empresas farmacêuticas e de biotecnologia, organizações de investigação por contrato, fabricantes de dispositivos médicos, institutos de investigação académicos e governamentais e outros), distribuidor (vendas diretas e vendas por concurso) - Tendências e previsões do setor para 2029.
Análise e insights do mercado de imagens de ensaios clínicos da Ásia-Pacífico
A crescente procura de tecnologia de imagem, seguida pelo aumento da prevalência de doenças crónicas devido ao aumento da população idosa e às iniciativas estratégicas dos participantes do mercado, como o lançamento de produtos, o avanço, a aquisição e os acordos, são os factores que deverão impulsionar o crescimento do mercado.
No entanto, espera-se que cenários de reembolso inadequados e desfavoráveis para dispositivos de imagem e a falta de padrões bem definidos nos instrumentos de imagem de ensaios clínicos restrinjam o crescimento do mercado.
Espera-se que as crescentes progressões tecnológicas na imagiologia de ensaios clínicos para o diagnóstico e tratamento de doenças crónicas impulsionem o crescimento do mercado. A Data Bridge Market Research analisa que o mercado de imagiologia de ensaios clínicos da Ásia-Pacífico crescerá a um CAGR de 8,8% durante o período de previsão de 2022 a 2029.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2022 a 2029 |
|
Ano base |
2021 |
|
Anos históricos |
2020 (personalizável para 2019-2014) |
|
Unidades Quantitativas |
Receita em milhões de dólares e preços em dólares |
|
Segmentos cobertos |
Por Produto e Serviços (Serviços e Software), Modalidade (Tomografia Computadorizada, Ressonância Magnética, Ecocardiografia, Medicina Nuclear, Tomografia por Emissão de Positrões, Raios X, Ecografia, Tomografia de Coerência Óptica e Outros), Aplicação (Oncologia, Neurologia, Endocrinologia, Cardiologia , dermatologia, hematologia e outros), utilizador final (empresas farmacêuticas e de biotecnologia, organizações de investigação por contrato, fabricantes de dispositivos médicos, institutos de investigação académicos e governamentais e outros), distribuidor (vendas diretas e vendas por concurso) |
|
Países abrangidos |
China, Japão, Coreia do Sul, Índia, Austrália, Singapura, Tailândia, Malásia, Indonésia, Filipinas e Resto da Ásia-Pacífico |
|
Participantes do mercado abrangidos |
Navitas Life Sciences, Resonance Health Analytical Services, ICON plc, Image Core Lab, Radiant Sage LLC, WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group e Invicro.LLC entre outros |
Definição de mercado
O ensaio clínico é um processo de desenvolvimento de novos medicamentos. Foi concebido para o tratamento potencial e os seus efeitos em humanos. Antes da comercialização de novos medicamentos, são realizados extensos testes clínicos para identificar compostos promissores e testes de segurança para determinar os possíveis riscos.
Em ensaios clínicos, as imagens médicas desempenham um papel significativo em resultados mais precisos e eficazes. Podem ser utilizadas diferentes tecnologias de imagem para elucidar e demonstrar as ações mecanísticas dos medicamentos. A imagem de ensaio clínico é o processo de análise clínica e intervenção médica através da criação de representações de imagens de partes internas do corpo. Possui várias tecnologias diferentes que são utilizadas para visualizar o corpo humano para monitorizar, tratar e diagnosticar condições médicas.
Num futuro próximo, decisões importantes relacionadas com a imagiologia de ensaios clínicos na descoberta de medicamentos serão tomadas por indivíduos que não só compreendem a biópsia, mas também podem utilizar as ferramentas de imagiologia dos ensaios clínicos e o conhecimento que libertam para desenvolver hipóteses e identificar alvos de qualidade.
Dinâmica do mercado de imagiologia de ensaios clínicos da Ásia-Pacífico
Motoristas
- Aumento das despesas em I&D
As empresas farmacêuticas e de imagiologia investem continuamente em I&D para oferecer aos clientes serviços de imagiologia inovadores para ensaios clínicos e aumentar a sua presença no mercado. A imagiologia médica desempenha um papel dinâmico no desenvolvimento clínico. Enquanto a indústria de imagiologia médica está em constante flutuação devido à implementação de novas tecnologias no mercado, as indústrias farmacêutica e de imagiologia continuam a crescer. Isto é atribuído ao aumento do investimento em empresas de imagiologia médica, juntamente com fusões e aquisições, bem como à adoção de inovação em tecnologias de imagiologia para apoiar ensaios clínicos de dispositivos médicos. O aumento dos gastos em I&D nas empresas farmacêuticas e biotecnológicas está a alimentar o crescimento do mercado.
Isto tem incentivado o desenvolvimento de novos produtos e programas altamente orientados para a investigação organizados nas indústrias biofarmacêuticas e uma grande preferência pelos estudos do genoma humano. O aumento dos gastos em atividades de I&D também desenvolve novos medicamentos e terapias para tratar doenças crónicas que impulsionam o crescimento do mercado. Isto ajuda as empresas farmacêuticas e biotecnológicas no desenvolvimento de novas tecnologias na categoria de ensaios clínicos de imagem, pelo que se espera que o aumento dos gastos em I&D impulsione o crescimento do mercado.
- Número crescente de organizações de investigação por contrato (CROs)
Contract Research Organization (CRO) is an organization that gives support for clinical trials and other research services to imaging and pharmaceutical industries in the form of outsourced pharmaceutical research services in terms of both drugs and medical devices. CRO helps imaging and pharmaceutical industries with the drug development process to reduce the cost and initiate the process of bringing clinical trials to develop the drug for a particular disease segment by using clinical trial imaging and other processes to overcome capacity gaps of the in-house research team for pharmaceutical and clinical research.
A huge number of CROs are engaged in monitoring the drug development process such as PAREXEL (U.S.), PRA Health Sciences (U.S.), Labcorp (U.S.), PPD (U.S.), Syneos Health (U.S.), ICON plc (Ireland), Envigo (U.K.), Charles River (U.S.) and SGS (Switzerland) among others. These are some CROs that are engaged to give support for clinical trials and other research services to the imaging and pharmaceutical industries. The increasing number of CROs is expected to drive market growth.
Opportunities
- Rise in Healthcare Expenditure
Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure.
For instance,
- National Health Expenditure Accounts (NHEA) published a report which stated that the U.S. healthcare expenditure grew by 4.6% in 2019. This estimates USD 3.80 trillion for the overall U.S. population reported by U.S. Centers for Medicare (CMS) and GDP health, spending in the U.S. is accounted to reach 17.7%.
Growing healthcare expenditure is also beneficial for further growth in the economic and healthcare sector and it is primarily fruitful as it significantly affects the development of better and advanced medical products in the market. Therefore, the surge in healthcare expenditure is expected to create a greater opportunity for the market.
- Strategic Initiatives by Market Players
The demand for clinical trial imaging is increasing in the market owing to the increased levels of R&D along with the growth of clinical trial imaging market aided by the desire for innovative medications. Thus, the top market players have implemented a new strategy by developing new products and collaborating with other market players to improve business operations and profitability.
For instance,
- In February 2020, ICON plc acquired MedPass International, a European medical devices CRO, reimbursement and regulatory consultancy. This acquisition has reportedly helped in the expansion of the medical device and diagnostic research services of ICON in Europe.
These strategic initiatives by the market players, including acquisition, conferences and focused segment product launches, are helping them grow and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players may act as an opportunity for market growth.
Restraints/Challenges
- High-Risk Radiation Causing Diseases
In clinical medical imaging, radiation is absorbed by the body which can harm molecular structures inside the patient’s body. High doses of radiation can affect human cells including loss of hair, skin burns and increased incidence of cancer. The estimated risk of developing fatal cancer is one in 2000 after going through a radiation dose of 10 mSv in a CT scan.
For instance,
- According to Radiological Society of America (RSNA), 1% to 2% of all cancers in the U.S. are caused by CT scans and the American Cancer Society identified CT scans and X-rays as one of the reasons for breast cancer, brain cancer and other cancers
- According to the Center for Disease Control and Prevention, exposure to high levels of radiation results in acute radiation syndrome. The amount of radiation that a person's body absorbs is called the radiation dose.
The high-risk radiation that occurs, would decrease the usage and sale of clinical trial imaging devices, thereby affecting the credibility of manufacturers involved in this market. Therefore, the high-risk radiation-causing diseases are expected to restrain the market growth.
- Strict Regulatory Policies
The healthcare industry is regulated by a structure of laws, rules & regulations that are extensive and complex.
For instance,
- In April 2018, the U.S. FDA released updated Guidance for Clinical Trial Imaging Endpoint Process Standards for the industry which includes the quality of imaging data obtained in clinical trials
- Biotechnology and pharmaceutical industries need to take first approval from the FDA for the process of drug development. They have to submit an Investigational New Drug (IND) application to the FDA before beginning clinical research.
COVID-19 Impact on the Asia-Pacific Clinical Trial Imaging Market
Diagnostic imaging services have been time-consuming and complicated by the need for strict infection control and prevention practices developed to contain the risk of transmission and protect healthcare personnel. Hence, the decision to image suspected patients or COVID-19-positive patients is based on their impact on the improvement of patient status. There have definitely been reduced volumes in outpatient medical imaging clinics due to social distancing regulations and lockdowns in Asia-Pacific region. This reduced the available appointments which led to longer waiting lists for exams such as ultrasound and interventional procedures.
Recent Developments
- Em janeiro de 2022, a Clario estabeleceu uma parceria com a XingImaging, uma empresa de produção de radiofármacos e aquisição de tomografia por emissão de positrões (PET), para realizar ensaios clínicos de imagiologia PET para testar novas terapêuticas na China. A parceria oferece a partilha de recursos conjuntos e especialistas em neurociências da Clario e da XingImaging para acelerar o início de ensaios clínicos e descoberta de medicamentos na China.
- Em novembro de 2021, foi constituída a Clario. A ERT e a Bioclínica fundiram-se para formar a Clario. A formação de uma nova empresa resultou na distribuição de software e serviços de imagiologia clínica e no aumento das vendas.
Âmbito do mercado de imagens de ensaios clínicos da Ásia-Pacífico
O mercado de imagiologia de ensaios clínicos da Ásia-Pacífico está segmentado em cinco segmentos com base nos produtos e serviços, modalidade, aplicação, utilizador final e distribuidor. O crescimento entre estes segmentos irá ajudá-lo a analisar segmentos de crescimento escasso nas indústrias e fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para os ajudar a tomar decisões estratégicas para identificar as principais aplicações do mercado.
Produtos e Serviços
- Serviços
- Software
Com base nos produtos e serviços, o mercado está segmentado em serviços e software.
Modalidade
- Tomografia Computadorizada
- Imagem por ressonância magnética
- Ecocardiografia
- Medicina Nuclear
- Tomografia por emissão de positrões
- raio X
- Ultrassom
- Tomografia de Coerência Óptica
- Outros
Com base na modalidade, o mercado está segmentado em tomografia computorizada , ressonância magnética , ecocardiografia, medicina nuclear, tomografia por emissão de positrões, raio X, ecografia, tomografia de coerência óptica e outros.
Aplicação
- Oncologia
- Neurologia
- Cardiologia
- Endocrinologia
- Dermatologia
- Hematologia
- Outros
Com base na aplicação, o mercado está segmentado em oncologia , neurologia, cardiologia, endocrinologia, dermatologia, hematologia e outras.
Utilizador final
- Organizações de investigação contratada
- Empresas farmacêuticas e de biotecnologia
- Fabricantes de dispositivos médicos
- Institutos de Investigação Académica e Governamental
- Outros
Com base no utilizador final, o mercado está segmentado em organizações de investigação por contrato , empresas farmacêuticas e de biotecnologia, fabricantes de dispositivos médicos, institutos de investigação académicos e governamentais e outros.
Distribuidor
- Vendas Diretas
- Vendas de propostas
Com base no distribuidor, o mercado está segmentado em vendas diretas e vendas por concurso.
Análise/perspetivas regionais do mercado de imagiologia de ensaios clínicos da Ásia-Pacífico
O mercado de imagiologia de ensaios clínicos da Ásia-Pacífico é analisado e os insights e tendências do tamanho do mercado são fornecidos por regiões, produtos e serviços, modalidade, aplicação, utilizador final e distribuidor, como mencionado acima.
Os países abrangidos neste relatório de mercado são a China, Japão, Coreia do Sul, Índia, Austrália, Singapura, Tailândia, Malásia, Indonésia, Filipinas e Resto da Ásia-Pacífico. Espera-se que a China domine o mercado, uma vez que as imagens clínicas são seguras e convenientes de utilizar. O papel vital do governo da China na configuração e estabelecimento de fornecedores nacionais no espaço de diagnóstico por imagem na China é um dos principais factores que deverão impulsionar o crescimento do mercado.
A secção do país do relatório também fornece fatores individuais que impactam o mercado e alterações nas regulamentações do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como novas vendas, vendas de reposição, demografia do país, epidemiologia de doenças e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e a disponibilidade das marcas da Ásia-Pacífico e os desafios enfrentados devido à grande ou escassa concorrência do impacto das marcas locais e nacionais nos canais de vendas, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.
Análise do panorama competitivo e da quota de mercado de imagens de ensaios clínicos da Ásia-Pacífico
O panorama competitivo do mercado de imagiologia de ensaios clínicos da Ásia-Pacífico fornece detalhes sobre o concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em I&D, novas iniciativas de mercado, presença na Ásia-Pacífico, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produtos, largura e amplitude do produto e domínio da aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado de imagiologia de ensaios clínicos da Ásia-Pacífico.
Alguns dos principais players que operam no mercado são a Navitas Life Sciences, Resonance Health Analytical Services, ICON plc, Image Core Lab, Radiant Sage LLC, WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group e Invicro.LLC, entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCTS AND SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING R&D EXPENDITURE
6.1.2 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS)
6.1.3 INCREASING INCIDENCE OF CHRONIC DISEASES
6.1.4 GROWTH IN THE PHARMACEUTICAL AND IMAGING INDUSTRIES
6.2 RESTRAINTS
6.2.1 HIGH-RISK RADIATION CAUSING DISEASES
6.2.2 HIGH IMPLEMENTATION COST OF IMAGING SYSTEMS
6.3 OPPORTUNITIES
6.3.1 RISE IN HEALTHCARE EXPENDITURE
6.3.2 STRATEGIC INITIATIVES BY KEY PLAYERS
6.3.3 DEVELOPMENT OF INNOVATIVE IMAGING MODALITIES AND CONTRAST AGENTS
6.4 CHALLENGES
6.4.1 STRICT REGULATORY POLICIES
6.4.2 COST OF CLINICAL TRIALS
7 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES
7.1 OVERVIEW
7.2 SERVICES
7.2.1 OPERATIONAL IMAGING SERVICES
7.2.2 READ ANALYSIS SERVICES
7.2.3 TRIAL DESIGN CONSULTING SERVICES
7.2.4 SYSTEM AND TECHNICAL SUPPORT SERVICES
7.3 SOFTWARE
8 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY MODALITY
8.1 OVERVIEW
8.2 COMPUTED TOMOGRAPHY
8.3 MAGENTIC RESONANCE IMAGING
8.4 ECHOCARDIOGRAPHY
8.5 NUCLEAR MEDICINE
8.6 POSITRON EMISSION TOMOGRAPHY
8.7 X-RAY
8.8 ULTRASOUND
8.9 OPTICAL COHERENCE TOMOGRAPHY
8.1 OTHERS
9 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 ONCOLOGY
9.2.1 X-RAY
9.2.2 ULTRASOUND
9.2.3 COMPUTED TOMOGRAPHY
9.2.4 MAGNETIC RESONANCE IMAGING
9.2.5 NUCLEAR MEDICINE
9.2.6 POSITRON EMISSION TOMOGRAPHY
9.2.7 OPTICAL COHERENCE TOMOGRAPHY
9.2.8 ECHOCARDIOGRAPHY
9.2.9 OTHERS
9.3 NEUROLOGY
9.3.1 COMPUTED TOMOGRAPHY
9.3.2 MAGNETIC RESONANCE IMAGING
9.3.3 POSITRON EMISSION TOMOGRAPHY
9.3.4 NUCLEAR MEDICINE
9.3.5 X-RAY
9.3.6 ULTRASOUND
9.3.7 OPTICAL COHERENCE TOMOGRAPHY
9.3.8 ECHOCARDIOGRAPHY
9.3.9 OTHERS
9.4 CARDIOLOGY
9.4.1 ECHOCARDIOGRAPHY
9.4.2 MAGNETIC RESONANCE IMAGING
9.4.3 COMPUTED TOMOGRAPHY
9.4.4 POSITRON EMISSION TOMOGRAPHY
9.4.5 NUCLEAR MEDICINE
9.4.6 X-RAY
9.4.7 ULTRASOUND
9.4.8 OPTICAL COHERENCE TOMOGRAPHY
9.4.9 OTHERS
9.5 ENDOCRINOLOGY
9.5.1 COMPUTED TOMOGRAPHY
9.5.2 MAGNETIC RESONANCE IMAGING
9.5.3 ECHOCARDIOGRAPHY
9.5.4 POSITRON EMISSION TOMOGRAPHY
9.5.5 NUCLEAR MEDICINE
9.5.6 X-RAY
9.5.7 ULTRASOUND
9.5.8 OPTICAL COHERENCE TOMOGRAPHY
9.5.9 OTHERS
9.6 DERMATOLOGY
9.6.1 ULTRASOUND
9.6.2 X-RAY
9.6.3 MAGNETIC RESONANCE IMAGING
9.6.4 COMPUTED TOMOGRAPHY
9.6.5 OPTICAL COHERENCE TOMOGRAPHY
9.6.6 POSITRON EMISSION TOMOGRAPHY
9.6.7 NUCLEAR MEDICINE
9.6.8 ECHOCARDIOGRAPHY
9.6.9 OTHERS
9.7 HEMATOLOGY
9.7.1 ULTRASOUND
9.7.2 COMPUTED TOMOGRAPHY
9.7.3 MAGNETIC RESONANCE IMAGING
9.7.4 X-RAY
9.7.5 POSITRON EMISSION TOMOGRAPHY
9.7.6 NUCLEAR MEDICINE
9.7.7 OPTICAL COHERENCE TOMOGRAPHY
9.7.8 ECHOCARDIOGRAPHY
9.7.9 OTHERS
9.8 OTHERS
10 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY END USER
10.1 OVERVIEW
10.2 CONTRACT RESEARCH ORGANIZATION
10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
10.4 MEDICAL DEVICE MANUFACTURERS
10.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
10.6 OTHERS
11 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR
11.1 OVERVIEW
11.2 DIRECT SALES
11.3 TENDER SALES
12 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY REGION
12.1 ASIA-PACIFIC
12.1.1 CHINA
12.1.2 JAPAN
12.1.3 SOUTH KOREA
12.1.4 INDIA
12.1.5 AUSTRALIA
12.1.6 SINGAPORE
12.1.7 THAILAND
12.1.8 MALAYSIA
12.1.9 INDONESIA
12.1.10 PHILIPPINES
12.1.11 REST OF ASIA-PACIFIC
13 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 NAVITAS LIFE SCIENCES
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENTS
15.2 RESONANCE HEALTH ANALYTICAL SERVICES
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 CLARIO
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.4 PARAXEL
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 BIOTELEMETRY, A PHILIPS COMPANY
15.5.1 COMPANY SNAPSHOT
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ICON PLC
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.7 MEDIAN TECHNOLOGIES
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 PERSPECTUM
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 ANAGRAM 4 CLINICAL TRIALS
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 CALYX
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 IMAGE CORE LAB
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 INVICRO. LLC. (A SUBSIDIARY OF KONICA MINOLTA)
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 IXICO PLC
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 QUOTIENT SCIENCES
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 RADIANT SAGE LLC
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 WIRB-COPERNICUS GROUP
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 WORLDCARE CLINICAL
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tabela
TABLE 1 COST OF CLINICAL TRIAL PHASE 2 AND PHASE 3
TABLE 2 HUGE R&D COST IN THE U.S. FOR DIFFERENT PHASES
TABLE 3 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC SOFTWARE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC COMPUTED TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC MAGNETIC RESONANCE IMAGING IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC ECHOCARDIOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC NUCLEAR MEDICINE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC POSITRON EMISSION TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC X-RAY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC ULTRASOUND IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC OPTICAL COHERENCE TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC CONTRACT RESEARCH ORGANIZATION IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 ASIA PACIFIC MEDICAL DEVICE MANUFACTURERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 38 ASIA PACIFIC DIRECT SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 ASIA PACIFIC TENDER SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC NEUROLOGY CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION,2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 50 ASIA-PACIFIC HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 51 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 53 CHINA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 54 CHINA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 55 CHINA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 56 CHINA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 57 CHINA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 58 CHINA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 59 CHINA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 60 CHINA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 61 CHINA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 62 CHINA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 63 CHINA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 CHINA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 65 JAPAN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 66 JAPAN SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 67 JAPAN CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 68 JAPAN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 69 JAPAN ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 JAPAN NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 71 JAPAN ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 72 JAPAN CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 JAPAN DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 74 JAPAN HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 75 JAPAN CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 76 JAPAN CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 77 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 78 SOUTH KOREA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 79 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 80 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 81 SOUTH KOREA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 82 SOUTH KOREA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 83 SOUTH KOREA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 SOUTH KOREA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 85 SOUTH KOREA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 86 SOUTH KOREA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 87 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 88 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 89 INDIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 90 INDIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 91 INDIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 92 INDIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 93 INDIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 94 INDIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 95 INDIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 96 INDIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 97 INDIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 98 INDIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 99 INDIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 100 INDIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 101 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 102 AUSTRALIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 103 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 104 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 105 AUSTRALIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 106 AUSTRALIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 107 AUSTRALIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 108 AUSTRALIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 109 AUSTRALIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 110 AUSTRALIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 111 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 112 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 113 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 114 SINGAPORE SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 115 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 116 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 117 SINGAPORE ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 118 SINGAPORE NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 119 SINGAPORE ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 120 SINGAPORE CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 121 SINGAPORE DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 122 SINGAPORE HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 123 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 124 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 125 THAILAND CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 126 THAILAND SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 127 THAILAND CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 128 THAILAND CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 129 THAILAND ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 130 THAILAND NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 131 THAILAND ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 132 THAILAND CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 133 THAILAND DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 134 THAILAND HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 135 THAILAND CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 136 THAILAND CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 137 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 138 MALAYSIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 139 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 140 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 141 MALAYSIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 142 MALAYSIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 143 MALAYSIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 144 MALAYSIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 145 MALAYSIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 146 MALAYSIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 147 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 148 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 149 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 150 INDONESIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 151 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 152 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 153 INDONESIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 154 INDONESIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 155 INDONESIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 156 INDONESIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 157 INDONESIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 158 INDONESIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 159 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 160 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 161 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 162 PHILIPPINES SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 163 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)
TABLE 164 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 165 PHILIPPINES ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 166 PHILIPPINES NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 167 PHILIPPINES ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 168 PHILIPPINES CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 169 PHILIPPINES DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 170 PHILIPPINES HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 171 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 172 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)
TABLE 173 REST OF ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
Lista de Figura
FIGURE 1 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: SEGMENTATION
FIGURE 11 THE INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATION AND RISING R&D EXPENDITURE ARE EXPECTED TO DRIVE THE ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET
FIGURE 14 WORLDWIDE BIOPHARMA COMPANIES R&D EXPENDITURE (IN USD MILLION)
FIGURE 15 THE MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
FIGURE 16 THE FUNCTION OF CRO
FIGURE 17 ESTIMATED NEW CANCER CASES, 2022
FIGURE 18 VALUE OF THE PHARMACEUTICAL SECTOR, WORLDWIDE, 2021 BY COUNTRY (IN MILLION U.S. DOLLARS)
FIGURE 19 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, 2021
FIGURE 20 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, 2022-2029 (USD MILLION)
FIGURE 21 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, CAGR (2022-2029)
FIGURE 22 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY MODALITY, 2021
FIGURE 24 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY MODALITY, 2022-2029 (USD MILLION)
FIGURE 25 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY MODALITY, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY MODALITY, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, 2021
FIGURE 28 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 29 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY END USER, 2021
FIGURE 32 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 33 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY END USER, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY END USER, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, 2021
FIGURE 36 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, 2022-2029 (USD MILLION)
FIGURE 37 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, CAGR (2022-2029)
FIGURE 38 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SNAPSHOT (2021)
FIGURE 40 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2021)
FIGURE 41 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 42 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 43 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: BY PRODUCT & SERVICES (2022-2029)
FIGURE 44 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
